← Back to patent-cliff list
CGT-1881
Tier C — Watch / tradeCGT-1881
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CXCR4
Indications (approved)：Multiple myeloma, Non-Hodgkin lymphoma, Haematopoietic stem cell transplantation, Haematological malignancy
Regional status
US
Phase I
2022-07-12
EU
-
China
Phase II
2023-05-17
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CGT-1881?
Approved indications include: Multiple myeloma, Non-Hodgkin lymphoma, Haematopoietic stem cell transplantation, Haematological malignancy.
When does the CGT-1881 patent expire?
No public expiry year is available for CGT-1881 yet; this page updates once verified.
How do I get a quote for CGT-1881 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03